A Chinese mRNA COVID vaccine is approved for the first time in Indonesia

The approval comes as somewhat of a surprise as Walvax, which has been conducting large late-stage trials of the vaccine in several countries including Indonesia, Mexico and China, has yet to publish efficacy readings that would show how well it can reduce the risk of COVID cases and deaths Indonesia said it has granted emergency use approval to an mRNA COVID-19 vaccine developed by a Chinese company, becoming the first country, ahead of even China, to do so. Indonesia's food and drugs agency (BPOM) greenlighted the use of Walvax Biotechnology's mRNA vaccine, which has been in development for more than two years and targets the original strain of the coronavirus The approval comes as somewhat of a surprise as Walvax, which has been conducting large late-stage trials of the vaccine in several countries including Indonesia, Mexico and China, has yet to publish efficacy readings that would show how well it can reduce the risk of COVID cases and deaths. Penny Lukito, head of the agency, told reporters the vaccine, now known as AWcorna, was 83.58% effective against wild-type coronavirus strains considered common and normal, though she added that its efficacy drops to 71.17% for the highly contagious Omicron variant. She did not provide details of the data and did not respond to Reuters queries seeking further comment. Walvax declined to comment. Share reaction for the Chinese company was muted, with the stock rising just 0.5%. Indonesia has previously granted emergency use approvals to other Chinese COVID shots before detailed efficacy data became available, though that was earlier on in the pandemic when Western-made products were in short supply. China has several mRNA candidates in development but the Walvax vaccine is the only candidate in large late-stage clinical trials. It was not immediately clear how widely the newly approved shot will be used in Indonesia, where more than 63% of its population is fully vaccinated. Health experts around the world also recommend using so-called bivalent COVID vaccines, which target both the original strain and the Omicron variant. Indonesia also uses mRNA COVID vaccines made by Pfizer -BioNTech and Moderna, but the AWcorna shot has a longer shelf life, remaining stable at 2-8 degrees Celsius for at least six months, according to its researchers. That could make the vaccine ideal for Indonesia, an archipelago of thousands of islands, and other countries which have poor logistics in remote areas. BPOM said the vaccine's less stringent storage requirements suited Indonesia, a tropical country, and it could be used as both a primary and a booster shot for adults. The vaccine will be locally produced by an Indonesian firm,

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!